palindore
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2008 (NCT00623324)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Dopamine D2 receptorPARTIAL AGONIST
DRD2 partial agonist
Chemistry & pharmacology
Loading structure…
SMILES
O=C1Cc2c(ccc3c2O[C@@H](CNCc2ccccc2)CO3)N1- Mol. weight
- 310.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2110659 ↗
- ChEMBLCHEMBL2104864 ↗
Also known as
- aplindore
- aplindore
- aplindore
- aplindore fumarate
- aplindore fumarate
- aplindore fumarate
- dab-452
- dab-452
- dab-452
- palindore
- palindore
- palindore fumarate
- palindore fumarate
- (s)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7h-1,4-dioxino(2,3-e)indol-8-one fumarate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00834327 | Phase 2 | Feb 1, 2009 | Neurogen Corporation |
| NCT00809302 | Phase 2 | Dec 1, 2008 | Neurogen Corporation |
| NCT00626418 | Phase 2 | Feb 1, 2008 | Ligand Pharmaceuticals |
| NCT00623324 | Phase 2 | Jan 1, 2008 | Ligand Pharmaceuticals |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ligand Pharmaceuticals | For profit | 2 | 2 | 1 | 2008 |
| Neurogen Corporation | For profit | 2 | 2 | 1 | 2008 |
2 organizations
Page 1 / 1